Edition:
United States

Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

22.78USD
25 May 2018
Change (% chg)

$0.20 (+0.89%)
Prev Close
$22.58
Open
$22.68
Day's High
$22.92
Day's Low
$22.36
Volume
373,890
Avg. Vol
626,103
52-wk High
$23.15
52-wk Low
$7.20

Select another date:

Mon, May 21 2018

BRIEF-Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. FDA

* IMMUNOMEDICS SUBMITS BIOLOGICS LICENSE APPLICATION FOR SACITUZUMAB GOVITECAN TO THE U.S. FOOD AND DRUG ADMINISTRATION

BRIEF-Immunomedics Announces Promising Data Of Sacituzumab Govitecan In Estrogen Receptor-Positive Metastatic Breast Cancer

* IMMUNOMEDICS ANNOUNCES PROMISING DATA OF SACITUZUMAB GOVITECAN IN ESTROGEN RECEPTOR-POSITIVE METASTATIC BREAST CANCER Source text for Eikon: Further company coverage:

BRIEF-Immunomedics Reports Q3 Loss Per Share $0.21

* IMMUNOMEDICS ANNOUNCES THIRD QUARTER FISCAL 2018 RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Immunomedics Q2 Loss Per Share $0.02

* IMMUNOMEDICS ANNOUNCES SECOND QUARTER FISCAL 2018 RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Immunomedics Announces Agreement With University Of Wisconsin Carbone Cancer Center To Expand Sacituzumab Govitecan Into Prostate Cancer

* IMMUNOMEDICS ANNOUNCES AGREEMENT WITH UNIVERSITY OF WISCONSIN CARBONE CANCER CENTER TO EXPAND SACITUZUMAB GOVITECAN (IMMU-132) INTO PROSTATE CANCER

BRIEF-Immunomedics, Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totalling $250 Mln

* IMMUNOMEDICS AND ROYALTY PHARMA ANNOUNCE ROYALTY FUNDING AND STOCK PURCHASE AGREEMENTS TOTALLING $250 MILLION

Select another date: